<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00520247</url>
  </required_header>
  <id_info>
    <org_study_id>2005L01101</org_study_id>
    <nct_id>NCT00520247</nct_id>
  </id_info>
  <brief_title>Effect of Enalapril Plus Folic Acid on Blood Pressure and Glycometabolism</brief_title>
  <official_title>Efficacy of Antihypertensive and Plasma Total Homocysteine Lowering Combined Therapy With Enalapril and Folic Acid in Hypertensive Patients:A Multicenter Double Blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Anhui Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combinded therapy with folic acid and enalapril may significantly decrease plasma total&#xD;
      homocysteine level and had beneficial effect on blood pressure reduction and glycometabolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:&#xD;
&#xD;
        1. Age≥18 years and less than 75 years&#xD;
&#xD;
        2. Essential hypertension patients&#xD;
&#xD;
        3. Sedentary systolic blood pressure≥140mmHg and less than 180mmHg, and/or sedentary&#xD;
           diastolic blood pressure≥90mmHg and less than 110mmHg&#xD;
&#xD;
        4. Reproductive women agree to take a reliable contraception measure during the trial&#xD;
&#xD;
        5. Written informed consent&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        1. Pregnant women&#xD;
&#xD;
        2. Women within lactateion period&#xD;
&#xD;
        3. Hypersensitive to Angiotensin-Converting Enzyme Inhibitor (ACEI) or folic acid&#xD;
&#xD;
        4. Easily hypersensitiveness&#xD;
&#xD;
        5. Diagnosed secondum hypertension or skeptical secondum hypertension&#xD;
&#xD;
        6. Severe hypertension (sedentary systolic blood pressure greater than or equal to 180 mmHg&#xD;
           and/or sedentary diastoleic blood pressure greater than or equal to 110 mmHg)&#xD;
&#xD;
        7. Severe diseases:&#xD;
&#xD;
             -  Cardiovascular system&#xD;
&#xD;
             -  Diagnosed cardia insufficiency (New York Health Association [NYHA] III level and&#xD;
                higher)&#xD;
&#xD;
             -  Hypertrophic obstructive cardiomyopathy (HOCM)&#xD;
&#xD;
             -  Clinical significantly Valvular Disease of the Heart (VDH)&#xD;
&#xD;
             -  Acute coronary syndrome or coronary artery interventional therapy or coronary&#xD;
                artery bypass graft within three months&#xD;
&#xD;
             -  Severe arrhythmia such as atrial flutter, atrial fibrillation, ventricular&#xD;
                arrhythmia above Lown ?, atrioventricular block above II level, etc.&#xD;
&#xD;
             -  Alimentary system disorders&#xD;
&#xD;
             -  Active virus hepatitis&#xD;
&#xD;
             -  Any of alanine aminotransferase (ALT), aspartate aminotransferase (AST),&#xD;
                galactosylhydroxylysyl glucosyltransferase (GGT), alkaline phosphatase (ALP), total&#xD;
                bilirubin (TBIL), Direct Bilirubin (DB) was above 2 times of it's normal value&#xD;
                upper limit, albumin (ALB) greater than 30 g/L&#xD;
&#xD;
             -  Stomach bulk resect and gastrojejunostomy, stomach intestine malabsorption&#xD;
&#xD;
           Urinary system:&#xD;
&#xD;
             -  Serum creatinine greater than or equal to 200 mmol/L&#xD;
&#xD;
             -  Diagnosed stenosis of renal artery, solitary kidney&#xD;
&#xD;
             -  Renal transplantation&#xD;
&#xD;
           Endocrine system:&#xD;
&#xD;
             -  Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (fasting glucose&#xD;
                greater than or equal to 11.1 mmol/L)&#xD;
&#xD;
             -  Diagnosed and uncontrolled hyperthyrosis&#xD;
&#xD;
           Respiratory system:&#xD;
&#xD;
             -  Chronic cough nervous or psyche system:&#xD;
&#xD;
             -  Transient Ischemia Attach (TIA) or stoke within 3 months&#xD;
&#xD;
             -  Severe peripheral nerve or vegetative nerve functional disturbance&#xD;
&#xD;
             -  Psyche or nervous system dysfunction&#xD;
&#xD;
             -  Drugs or alcohol dependence&#xD;
&#xD;
           Others:&#xD;
&#xD;
             -  Malignant tumor&#xD;
&#xD;
             -  Malnutrition, haematogenesis dysfunction, etc.&#xD;
&#xD;
        8. Taking other antihypertensive drugs&#xD;
&#xD;
        9. Taking folic acid or other Vitamin B groups&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
        1. Blood pressure of study participants was measured at baseline, 2th week, 4th week, 6th&#xD;
           week and at the end of trial&#xD;
&#xD;
        2. Subjects' plasma total homocysteine concentration were measured at baseline, 4th week&#xD;
           and at 8th week.&#xD;
&#xD;
      Secondary Outcome Measures:&#xD;
&#xD;
        1. Participants' living habit and life style were collected at baseline with the original&#xD;
           questionnaires.&#xD;
&#xD;
        2. A follow up questionnaire was sent out at 2th week, 4th week, 6th week and at the end of&#xD;
           the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure of study participants was measured at baseline, 2th week, 4th week, 6th week and at the end of trial Subjects' plasma total homocysteine concentration were measured at baseline, 4th week and at 8th week.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants' living habit and life style were collected at baseline with the original questionnaires. A follow up questionnaire was sent out at 2th week, 4th week, 6th week and at the end of the trial.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">443</enrollment>
  <condition>Plasma Total Homocysteine Level</condition>
  <condition>Blood Pressure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enalapril plus folic acid</intervention_name>
    <description>enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age≥18 years and less than 75 years&#xD;
&#xD;
          -  Essential hypertension patients&#xD;
&#xD;
          -  Sedentary systolic blood pressure≥140mmHg and less than 180mmHg, and/or sedentary&#xD;
             diastolic blood pressure≥90mmHg and less than 110mmHg&#xD;
&#xD;
          -  Reproductive women agree to take a reliable contraception measure during the trial&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Women within lactateion period&#xD;
&#xD;
          -  Hypersensitive to angiotensin-converting enzyme inhibitor (ACEI) or folic acid&#xD;
&#xD;
          -  Easily hypersensitiveness&#xD;
&#xD;
          -  Diagnosed secondum hypertension or skeptical secondum hypertension&#xD;
&#xD;
          -  Severe hypertension (sedentary systolic blood pressure≥180mmHg and/or sedentary&#xD;
             diastoleic blood pressure≥110mmHg)&#xD;
&#xD;
        Severe diseases:&#xD;
&#xD;
          -  Cardiovascular system:&#xD;
&#xD;
               -  Diagnosed cardia insufficiency (NYHAⅢ level and higher)&#xD;
&#xD;
               -  Hypertrophic obstructive cardiomyopathy (HOCM)&#xD;
&#xD;
               -  Clinical significantly valvular disease of the heart (VDH)&#xD;
&#xD;
               -  Acute coronary syndrome or coronary artery interventional therapy or coronary&#xD;
                  artery bypass graft within three months&#xD;
&#xD;
               -  Severe arrhythmia such as atrial flutter, atrial fibrillation, ventricular&#xD;
                  arrhythmia above Lown Ⅱ, atrioventricular block above Ⅱ level, et al&#xD;
&#xD;
          -  Alimentary system:&#xD;
&#xD;
               -  Active virus hepatitis&#xD;
&#xD;
               -  Any of alanine aminotransferase (ALT), aspartate aminotransferase (AST),&#xD;
                  galactosylhydroxylysyl glucosyltransferase (GGT), alkaline phosphatase (ALP),&#xD;
                  total bilirubin (TBIL), direct bilirubin (DB) was above 2 times of it's normal&#xD;
                  value upper limit, albumin (ALB)&gt;30g/L&#xD;
&#xD;
               -  Stomach bulk resect and gastrojejunostomy, stomach intestine malabsorption&#xD;
&#xD;
          -  Urinary system:&#xD;
&#xD;
               -  Serum creatinine≥200mmol/L&#xD;
&#xD;
               -  Diagnosed stenosis of renal artery, solitary kidney&#xD;
&#xD;
               -  Renal transplantation&#xD;
&#xD;
          -  Endocrine system:&#xD;
&#xD;
               -  Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (fasting&#xD;
                  glucose≥11.1mmol/L)&#xD;
&#xD;
               -  Diagnosed and uncontrolled hyperthyrosis&#xD;
&#xD;
          -  Respiratory system:&#xD;
&#xD;
               -  Chronic cough&#xD;
&#xD;
               -  Nervous or psyche system&#xD;
&#xD;
               -  Transient ischemia attach (TIA) or stoke within 3 months&#xD;
&#xD;
               -  Severe peripheral nerve or vegetative nerve functional disturbance&#xD;
&#xD;
               -  Psyche or nervous system dysfunction&#xD;
&#xD;
               -  Drugs or alcohol dependence&#xD;
&#xD;
          -  Others:&#xD;
&#xD;
               -  Malignant tumor, malnutrition, haematogenesis dysfunction, et al&#xD;
&#xD;
               -  Taking other antihypertensive drugs&#xD;
&#xD;
               -  Taking folic acid or other Vitamin B groups&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Liu, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Peking University First Hopital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inistitute for Biomedicine, Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>August 17, 2007</study_first_submitted>
  <study_first_submitted_qc>August 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2007</study_first_posted>
  <last_update_submitted>August 22, 2007</last_update_submitted>
  <last_update_submitted_qc>August 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2007</last_update_posted>
  <keyword>enalapril</keyword>
  <keyword>folic acid</keyword>
  <keyword>hyperglycemia</keyword>
  <keyword>hypertension</keyword>
  <keyword>fasting plasma glucose</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Enalapril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

